BioCentury
ARTICLE | Clinical News

Brincidofovir: Phase III started

November 2, 2015 8:00 AM UTC

Chimerix began the double-blind, active-controlled, Phase III SURPASS trial to compare twice-weekly 100 mg brincidofovir vs. valganciclovir for up to 14 weeks post-transplant in about 520 kidney trans...